Using an app to educate patients about Hepatitis C in the emergency department
Official title: Use of a Patient-Centered Electronic App to Increase Emergency Department Patient's Knowledge on HCV Infection, Disease Progression, and Care to Improve the HCV Care Continuum
Run by Johns Hopkins University · NCT04162938 · Data updated 2026-11-12
This study is testing an app that helps patients in the emergency department learn more about Hepatitis C to improve their understanding and get them started on treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 308 (estimated) |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Status | Recruiting |
| Started | March 24, 2022 |
| Main results expected | April 2027 |
| Study ends | July 2027 |
| Registry record updated | September 29, 2026 |
| Trial ID | NCT04162938 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who are HCV positive and do not have HCV RNA information.
✕Probably not a fit
Patients who are younger than 18, unable to provide informed consent, have altered mental status, are incarcerated, or critically ill may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of a patient-centered electronic app designed to enhance knowledge and understanding of Hepatitis C (HCV) among patients in an urban emergency department. The app will provide personalized information about liver health, assess patients' knowledge and barriers to care, and deliver tailored educational content through videos and information sheets. By improving patients' comprehension of their HCV diagnosis and care options, the study seeks to increase linkage to care rates and treatment initiation for HCV. The trial will be conducted at Johns Hopkins Hospital in Baltimore, targeting HCV-infected patients who are unaware of their HCV RNA status.
Why it matters
Potential benefit: If successful, this approach could significantly improve patient engagement and outcomes in the management of Hepatitis C.
How similar studies have gone: Other studies have shown promise in using educational interventions to improve patient outcomes in HCV care, indicating that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Johns Hopkins Hospital ED patient * 18 years or older * HCV positive without HCV RNA information Exclusion Criteria: * Younger than 18 years of age * Unable to provide informed consent * Altered mental status * Incarcerated * Critically ill
Where it's running
-
Johns Hopkins University
Baltimore, Maryland, United States Recruiting
Study contacts
- Principal investigator: Yu-Hsiang Hsieh, PhD — Johns Hopkins University
- Study coordinator: Deanna Myer
- Email: dmyer1@jhmi.edu
- Phone: 443-287-6985
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Glecaprevir/pibrentasvir started during pregnancy for women with hepatitis C, with or without HIV
This trial will test whether taking glecaprevir/pibrentasvir during pregnancy is safe and how the drug is processed in pregnant women who have hepatitis C, including those who also have HIV, and will follow their infants for 10 weeks after birth.
-
Evaluating hepatitis C treatment during pregnancy
This study tests how well a new hepatitis C treatment works for pregnant adults with a history of drug use and looks at their experience during the treatment.
-
Decentralized treatment for hepatitis C in Brazil
This study is testing a new way to treat hepatitis C in Brazil using a medication called Epclusa to see if it helps more people get the care they need compared to traditional methods.
-
Helping young people who inject drugs start treatment for Hepatitis C
This study tests a new support program to help young adults who inject drugs start treatment for Hepatitis C and see if it works better than regular care.
-
Simplified hepatitis C testing with same-day treatment for people who inject drugs in Armenia, Georgia and Tanzania
This project will test whether a simplified pathway that starts hepatitis C treatment the same day after a quick antibody test helps people who inject drugs in Armenia, Georgia, and Tanzania get treated and cured faster than the usual antibody-plus-RNA pathway.
-
Point-of-care testing program for Hepatitis C screening
This study is testing if quick Hepatitis C tests done during a single visit can help more at-risk adults get diagnosed and start treatment faster.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.